Max Lataillade

Incyte (United States) — United States

Medicine · Health Sciences

22h-index2.0kcitations70works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(58), HIV Research and Treatment(52), HIV/AIDS Research and Interventions(37), HIV-related health complications and treatments(13), Hepatitis C virus research(6)

Publications70 total

Abstract B062: Leronlimab is associated with long-term survival in metastatic TNBC: Enhancing PD-L1 expression, ICI response, and modulates T cell exhaustion
Cancer Immunology Research·2026
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study
EClinicalMedicine·2025· 1 citedOpen Access
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study
EClinicalMedicine·2025Open Access
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
UNC Libraries·2025Open Access
Abstract B019: CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC.
Cancer Immunology Research·2025
Modèles multivariés étendus pour identifier les facteurs prédictifs de la réponse virologique au fostemsavir dans l'étude BRIGHTE
Médecine et Maladies Infectieuses Formation·2024
Augmentation des lymphocytes T CD4+ et réduction générale des biomarqueurs inflammatoires indépendamment du taux de lymphocytes T CD4+ à l'inclusion pendant 240 semaines de traitement par fostemsavir (FTR) + traitement de fond optimisé (TFO) dans l'étude BRIGHTE
Médecine et Maladies Infectieuses Formation·2024
365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Open Forum Infectious Diseases·2023Open Access
Effects of the <scp>HIV</scp>‐1 maturation inhibitor <scp>GSK3640254</scp> on <scp>QT</scp> interval in healthy participants
Pharmacology Research & Perspectives·2023· 1 citedOpen Access
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
Infectious Diseases and Therapy·2023· 17 citedOpen Access
Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults
British Journal of Clinical Pharmacology·2023Open Access
Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants
British Journal of Clinical Pharmacology·2023· 3 citedOpen Access
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection
Antiviral Therapy·2022· 1 citedOpen Access
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Antimicrobial Agents and Chemotherapy·2022· 17 citedOpen Access
Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
Clinical Pharmacology in Drug Development·2022· 5 citedOpen Access
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
Clinical Infectious Diseases·2022· 20 citedOpen Access
Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
British Journal of Clinical Pharmacology·2021· 7 citedOpen Access
Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study
Journal of AIDS and HIV Treatment·2021· 4 citedOpen Access
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
Journal of Antimicrobial Chemotherapy·2021· 12 citedOpen Access
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
Patient·2021· 7 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Samit R. Joshi(19), Mark Krystal(15), George J. Hanna(14), David Stock(11), Jean‐Michel Molina(8), Peter Ackerman(8), Cyril Llamoso(8), Michael J. Kozal(8), Neelanjana Ray(8), Jacob Lalezari(8), Melanie Thompson(7), Gulam Latiff(7), Margaret Gartland(7), Amy Pierce(7), Rong Yang(6), Michael D. Miller(6), Ira B. Dicker(6), Sandra Treviño‐Pérez(6), Teodora Pene Dumitrescu(6), Princy Kumar(5)